Astrazeneca: Zegfrovy Now Available In US For NSCLC
Astrazeneca: Zegfrovy Now Available In US For NSCLC
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AstraZeneca’s ZEGFROVY Now Available in the US for EGFR-Mutated NSCLC
AstraZeneca announced US availability of ZEGFROVY (sunvozertinib) for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations detected by an FDA-approved test.